Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Researchers sought to determine whether venetoclax plus decitabine would lead to enhanced feasibility for allogeneic HSCT in patients with AML.

California-based Apollomics had been testing uproleselan as an adjunct to chemotherapy in relapsed and refractory acute ...

A workaholic doctor thought her extreme back pain was just stress-related when she was diagnosed with acute myeloid leukaemia ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Apollomics Inc., a late-stage clinical biopharmaceutical company, said its leukemia drug failed to pass trials in China, a ...

Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Shares of Curis jumped after the company released what it assessed as positive data from a study of its in-development treatment for leukemia. The stock was up 33%, to $4.07, in midday trading ...

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the opening of ...